ATyr Pharma Company Insiders
| LIFE Stock | USD 1.64 0.04 2.50% |
ATyr Pharma's insiders are aggressively buying. The analysis of the overall insider sentiment regarding aTyr Pharma suggests that all insiders are extremely bullish. ATyr Pharma employs about 56 people. The company is managed by 34 executives with a total tenure of roughly 246 years, averaging almost 7.0 years of service per executive, having 1.65 employees per reported executive.
| John Mendlein Chairman CEO and Executive Chairman, Board of Directors |
| John Clarke Chairman Non-Executive Independent Chairman of the Board |
ATyr Pharma's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-12-11 | Sanjay Shukla | Acquired 3000 @ 1.17 | View | ||
| 2023-05-10 | Paul Schimmel | Acquired 200000 @ 2.25 | View |
Monitoring ATyr Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ATyr |
ATyr Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.3172) % which means that it has lost $0.3172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6231) %, meaning that it created substantial loss on money invested by shareholders. ATyr Pharma's management efficiency ratios could be used to measure how well ATyr Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to -0.43. In addition to that, Return On Capital Employed is expected to decline to -0.55. At present, ATyr Pharma's Deferred Long Term Asset Charges is projected to decrease significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 1.4 B, whereas Non Current Assets Total are forecasted to decline to about 18.1 M.The current year's Common Stock Shares Outstanding is expected to grow to about 56.3 M, whereas Net Loss is projected to grow to (38.8 M).
ATyr Pharma Workforce Comparison
aTyr Pharma is rated below average in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 1,073. ATyr Pharma holds roughly 56.0 in number of employees claiming about 5% of equities under Health Care industry.
ATyr Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ATyr Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ATyr Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ATyr Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sanjay Shukla over three weeks ago Acquisition by Sanjay Shukla of 3000 shares of ATyr Pharma at 1.17 subject to Rule 16b-3 | ||
Sanjay Shukla over two months ago Exercise or conversion by Sanjay Shukla of 10375 shares of ATyr Pharma subject to Rule 16b-3 | ||
Sanjay Shukla over three months ago Acquisition by Sanjay Shukla of 600000 shares of ATyr Pharma subject to Rule 16b-3 | ||
Sanjay Shukla over three months ago Purchase by Sanjay Shukla of 1422 shares of ATyr Pharma | ||
Sanjay Shukla over six months ago Purchase by Sanjay Shukla of 15000 shares of ATyr Pharma | ||
Paul Schimmel over six months ago Acquisition by Paul Schimmel of 12000 shares of ATyr Pharma subject to Rule 16b-3 | ||
Sanjay Shukla over six months ago Exercise or conversion by Sanjay Shukla of 10375 shares of ATyr Pharma subject to Rule 16b-3 | ||
Paul Schimmel over six months ago Exercise or conversion by Paul Schimmel of 6000 shares of ATyr Pharma subject to Rule 16b-3 |
ATyr Pharma Notable Stakeholders
An ATyr Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ATyr Pharma often face trade-offs trying to please all of them. ATyr Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ATyr Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MS MD | CEO President | Profile | |
| John Mendlein | CEO and Executive Chairman, Board of Directors | Profile | |
| John Clarke | Non-Executive Independent Chairman of the Board | Profile | |
| Melissa Ashlock | Vice President - External Scientific Alliances and Human Genetics | Profile | |
| Andrew Cubitt | Vice President - Product Protection | Profile | |
| John McKew | Vice President - Research | Profile | |
| Holly Chrzanowski | Vice President - Enterprise Talent and Organization | Profile | |
| Ashraf Amanullah | Vice President Biologics Development and Manufacturing | Profile | |
| Fred Ramsdell | Vice President - Immunology | Profile | |
| Kelly Blackburn | Vice President - Clinical Affairs | Profile | |
| David King | Senior Vice President - Research | Profile | |
| Grove Matsuoka | Senior Vice President Product Programs and Planning | Profile | |
| Stan Blackburn | Acting CFO and Financial Consultant | Profile | |
| Jeffrey Hatfield | Director | Profile | |
| Mark Goldberg | Non-Executive Independent Director | Profile | |
| James Blair | Non-Executive Independent Director | Profile | |
| Srinivas Akkaraju | Non-Executive Independent Director | Profile | |
| Jane Gross | Director | Profile | |
| Svetlana Lucas | Director | Profile | |
| Timothy Coughlin | Director | Profile | |
| Kathryn Falberg | Non-Executive Independent Director | Profile | |
| Amir Nashat | Non-Executive Independent Director | Profile | |
| Paul Schimmel | Founder, Director and Member of Compensation Committee | Profile | |
| John Blake | Principal Accounting Officer and VP of Fin. | Profile | |
| Danielle Campbell | VP Resource | Profile | |
| Sanuj Ravindran | Chief Business Officer | Profile | |
| Sanjay Shukla | Chief Medical Officer | Profile | |
| XiangLei Yang | Founder | Profile | |
| Ying Buechler | Executive Manufacturing | Profile | |
| Leslie Nangle | Vice Research | Profile | |
| Jill Broadfoot | Chief Officer | Profile | |
| Peter Villiger | Vice Development | Profile | |
| Nancy Krueger | General Secretary | Profile | |
| Ashlee Dunston | Director Communications | Profile |
About ATyr Pharma Management Performance
The success or failure of an entity such as aTyr Pharma often depends on how effective the management is. ATyr Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ATyr management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ATyr management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.56) | (0.58) |
The data published in ATyr Pharma's official financial statements usually reflect ATyr Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of aTyr Pharma. For example, before you start analyzing numbers published by ATyr accountants, it's critical to develop an understanding of what ATyr Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ATyr Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ATyr Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ATyr Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of aTyr Pharma. Please utilize our Beneish M Score to check the likelihood of ATyr Pharma's management manipulating its earnings.
ATyr Pharma Workforce Analysis
Traditionally, organizations such as ATyr Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ATyr Pharma within its industry.ATyr Pharma Manpower Efficiency
Return on ATyr Pharma Manpower
| Revenue Per Employee | 6.3K | |
| Revenue Per Executive | 10.4K | |
| Net Loss Per Employee | 899.8K | |
| Net Loss Per Executive | 1.5M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 2.5M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.Note that the aTyr Pharma information on this page should be used as a complementary analysis to other ATyr Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for ATyr Stock analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is ATyr Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATyr Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 0.007 | Quarterly Revenue Growth (1.00) | Return On Assets (0.32) | Return On Equity (0.62) |
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATyr Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATyr Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATyr Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.